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A 38-year-old woman with aggressive clinical course of chronic lymphocytic leukemia (CLL) was treated with 8 courses of
R-CHOP. Clinical remission was achieved, while B-cell clonality remained. Allogeneic hematopoietic stem cell transplantation
was performed with reduced intensity conditioning (ﬂudarabine and 2-Gy total body irradiation). However, autologous he-
matopoietic recovery occurred within a month after the transplant. Nevertheless, B-cell clonality became undetectable at 14 days
after transplant, which has been kept so for over 10 years with clinical remission. Cytogenetic analyses were repeatedly performed
and demonstrated nonclonal chromosomal aberrations, although the patient did not develop any secondary malignancies. One
possible explanation for the clinical course is a very short-term allogeneic immune reaction helping eradication of residual
CLL cells.
1. Introduction
Chronic lymphocytic leukemia (CLL) is a clonal B-cell
neoplasm, which is generally slowly progressive but diﬃcult
to be cured even with current chemoimmunotherapy. Al-
logeneic hematopoietic stem cell transplantation (allo-
HSCT) is a possible therapeutic choice for disease cure,
although the indication of allo-HSCT for CLL is limited
because of the advances of treatment options with lower
morbidity. Here, we report a case of durable molecular
remission of CLL with autologous marrow recovery after
allo-HSCT. .e patient demonstrated the recovery of
recipient-derived hematopoietic system within one month
after allo-HSCT but did not show any signs of CLL relapse
even 10 years after allo-HSCT. .is is a report of a rare case
implying that a cure of CLL could be achieved possibly by a
very short-term allogeneic immune reaction. Repeated cy-
togenetic studies after autologous recovery are accompanied
with a detailed description of random chromosomal
abnormalities.
2. Case Presentation
A 38-year-old woman with systemic lymphadenopathy and
fever was admitted to a local hospital. Performance status
was 2 according to the Eastern Cooperative Oncology Group
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criteria [1]. White blood cell count (WBC) was 21 × 109/L,
with 91% of nucleated cells being small and
mature lymphocytes. Mild anemia (hemoglobin, 10.8 g/dl)
and moderate thrombocytopenia (platelet number, 46 × 109/
L) were also observed (Table 1). Flow cytometric analysis
revealed that the increased lymphocytes were positive for
CD5, CD19, CD20, CD23, and IgGλ (Figure 1(a)). IgH/
cyclinD1 translocation was negative in ﬂuorescence in situ
hybridization analysis. Cytogenetic analysis of bone marrow
cells demonstrated the normal karyotype. She also dem-
onstrated elevated levels of aspartate transaminase (156 IU/l;
normal 13–30U/l), alanine transaminase (139 IU/l; normal,
7–23U/l), lactate dehydrogenase (595 IU/l; normal, 124–
232U/l), and total bilirubin (1.8 g/dl; normal, 0.4–1.5mg/dl).
Soluble interleukin-2 receptor was also markedly elevated
(10,400U/ml; normal, 190–650U/ml; Table 1 and Figure 2).
Contrast computed tomography revealed multiple lymph-
adenopathy, hepatosplenomegaly, bilateral pleural eﬀusion,
and massive ascites. Bone marrow biopsy demonstrated a
remarkable inﬁltration of small mature lymphocytes (57% of
the total bone marrow cells). Immunophenotype of the
major population was the same as that of peripheral
blood lymphocytes. A small number of relatively large,
blastic lymphocytes were diﬀusely observed in the bone
marrow. Polymerase chain reaction (PCR) analysis dem-
onstrated a single complementarity determining region
(CDR-III) signal, indicating clonal B-cell proliferation.
Taken together, she was diagnosed to have CLL (Rai stage IV
and Binet stage C).
Because of her aggressive disease presentation and
suspect of Richter syndrome, R-CHOP therapy (rituximab
375mg/m2, cyclophosphamide 750mg/m2, daunorubicin
50mg/m2 for one day, and prednisolone 100mg/body for 5
days) was chosen as an initial therapy. After the treatment,
her lymphadenopathy, hepatosplenomegaly, pleural eﬀu-
sion, and ascites were improved and 8 courses of R-CHOP
were given.Morphologic CLL cells disappeared in peripheral
blood. However, ﬂow cytometric analysis revealed that
0.17% of the total bone marrow cells were leukemic cells and
that the same single CDR-III signal as the one detected at the
diagnosis was conﬁrmed by PCR. .ese observations sug-
gested the presence of minimum residual diseases (MRD),
even after additional three courses of rituximab
monotherapy.
Because of young age, suspect of Richter syndrome, and
remaining MRD, the patient was referred to the University
of Tsukuba Hospital 21 months after the diagnosis for allo-
HSCT..e graft was bone marrow from an unrelated female
donor with one-allele mismatched HLA. Nonmyeloablative
conditioning regimen was chosen containing ﬂudarabine
30mg/m2 for 3 days and 2-Gy total body irradiation.
Tacrolimus and short-term methotrexate were used for
graft-versus-host disease (GVHD) prophylaxis (Figure 2).
On day 14, neutrophil engraftment was achieved, and the
MRD judged by PCR for CDR-III became undetectable with
the bone marrow cells. Donor-cell chimerism in the bone
marrow was 70.4%, when evaluated by short tandem repeat-
(STR-) PCR analysis. However, a progressive neutropenia
was observed from day 20, when peripheral blood cells
showed decreased donor chimerism down to 14.2%. On day
24, STR-PCR of bone marrow cells revealed 100% recipient
type, suggesting rejection of the donor graft. Favorably,
however, the multilineage cytopenia was gradually im-
proved, and single CDR-III signal was never detected after
the transplant. On day 62, WBC was 34 × 109/L with 42.7%
neutrophils and 41.8% lymphocytes. Hemoglobin was
10.2 g/dl, and the platelet number was 146 × 109/L. .ese
observations suggested that autologous bone marrow re-
cover with remission of CLL. No apparent acute GVHD was
observed. Leukemic cells were never detected in the bone
Table 1: Laboratory ﬁndings at the initial diagnosis.
Peripheral blood
WBC 21 × 109/l
Seg 3%
Band 1%
Lymph 70%
A-lym 21%
Mono 2%
Eos 0%
Baso 1%
RBC 308 × 104/μl
Hb 10.8 g/dl
Plt 46 × 109/l
Coagulation
PT 12.1 sec
APTT 27.1 sec
Fib 241mg/dl
AT 86%
FDP 5.1 μg/ml
Blood chemistry
TP 6.0 g/dl
Alb 3.8 g/dl
AST 156U/l
ALT 139U/l
LDH 595 IU/l
GGT 319U/l
ALP 2022U/l
ChE 163U/l
T-bil 1.8mg/dl
D-bil 1.1mg/dl
AMY 58U/l
CK 29U/l
BUN 16mg/dl
Cre 0.7mg/dl
Na 142mEq/l
K 4.0mEq/l
Ca 9.1mg/dl
CRP 1.19mg/dl
β2MG 5.41mg/l
Ferritin 102.5 ng·ml
sIL-2R 10400U/ml
Immunology
IgG 615mg/dl
IgA 50mg/dl
IgM 17mg/dl
C3 124mg/dl
C4 36mg/dl
CH50 51.5U/ml
Bold means the abnormal laboratory value.
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marrow or peripheral blood in ﬂow cytometry even 10 years
after the transplant. .ere were no chronic GVHD-like
symptoms or signs. Cytogenetic studies were repeated 15
times over 10 years for the screening purpose to detect
emergence of clonal cells. In total, 299 metaphase cells were
analyzed, and abnormalities were found in 50 cells (16.7%,
Table 2). Abnormalities in 7q22 were found in four cells at 3
independent studies performed at 53 through 61 months
after the transplant. However, the 7q22 abnormalities were
detected only temporarily and were never found thereafter
until 136 months after the transplant. All the other ab-
normalities were seen only one time. All this agrees with the
concept of random chromosomal abnormalities (RCA) seen
in automarrow recovery after receiving high-dose ionizing
radiation exposure [2]. Despite the careful follow-up, the
patient has been evaluated not to develop any clonal dis-
orders such as myelodysplastic syndromes (MDS). Her
blood cell counts and lymphocytes number were within the
normal range at the last visit (140 months after the trans-
plant), and there was no dysplastic changes in peripheral
blood and bone marrow cells.
3. Discussion
CLL, the most common mature B-cell neoplasm in Cau-
casians, is generally prevalent in elderly people, although it is
also present in younger adults. In the current therapeutic
strategy for CLL [3–5], the indication of allo-HSCT is very
limited. In the report from Fred Hutchinson Cancer Re-
search Center, allo-HSCT with ﬂudarabine plus low-dose
total body irradiation regimen improved overall survival
(OS; 5-year OS, 50%) and progression-free survival (PFS; 5-
year PFS, 39%) in CLL patients [6]. However, the other
literatures reported that the risk of graft rejection in
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Figure 1: (a). Flow cytometric analysis of peripheral blood at diagnosis. □ means leukemic cell gate. Leukemic cells are positive in IgGλ,
CD20, CD19, CD23, CD5, and HLA-DR. (b) Hematoxylin and eosin staining of leukemic cells in the bone marrow clot (× 400). (c)
Immunostaining of CD20 (× 400).
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nonmyeloablative allo-HSCT for CLL was relatively high
(12–25% with T-cell depleted grafts and 5–6% with un-
manipulated grafts) [7]. High incidences of infectious
complication are also concerned in allo-HSCT for CLL.
Moreover, the recent advances of chemoimmunotherapy
with lower morbidity decrease the indication of allo-HSCT
for CLL. .erefore, allo-HSCT is currently considered only
for the relapsing patients with TP53 mutations and/or del
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Figure 2: Clinical course. Absolute number or white blood cells (WBC, •), lymphocytes (□), and soluble IL2-receptor (sIL-2R, ◆) were
shown in graph. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; Flu, ﬂudarabine; TBI, total body
irradiation; uBMT, unrelated bone marrow transplantation; sMTX, short-term methotrexate; CDR III, complementarity determining
region III.
Table 2: Random chromosomal abnormalities after autologous hematopoietic recovery.
Days after
the transplant
(month)
Karyotype (number of cells)
Number of
abnormal
karyotypes
Number of
the
metaphase
At diagnosis 46,XX[20] (0) (20)
45 (1) 46,XX,t(8;11)(p23;p21)[1] / 46,XX,t(8;22)(p21;p13)[1] / 46,XX[18] 2 20
172 (24) 46,XX,t(2;3)(p23;q29)[1] / 46,XX[19] 1 20
886 (29) 46,XX,add(1)(p11),add(2)(p11.2),−8,add(12)(q13),+mar1[3] / 46,XX [17] 3 20
1257 (41) 46,XX,t(3;3)(p11;p25)[2] / 46,X,t(X;8)(p22.3;q13)[1] / 46,XX,t(11;15)(q23;q15)[1] / 46,XX[15] 4 19
1623 (53) 46,XX,del(7)(q?)[3]
∗ / 46,XX,t(12;15)(q24.1;q22)[1] / 46,XX,add(4)(q12),add(6)(p21),der(6)
t(4;6)(q12;q21)[1] / 46,XX[15] 5 20
1819 (59) 46,XX,add(7)(q22)[1]
∗/46,XX,t(1;3)(p36.3;p21)[1] / 46,X,?t(X;16)(q22;q24),t(1;13)(p35.3;q14)
[1] / 46,XX,t(13;20)(q14;q13.1)[1] / 46,X,?inv(X)(p11.2q21),t(5;16)(q31;p13.3)[1] / 46,XX[15] 5 20
1861 (61) 46,XX,add(7)(q22)[2]∗/ 46,XX,del(7)(q22),add(19)(q13.3)[1]∗/ 46,XX[17] 3 20
2022 (66) 46,XX,t(5;11)(q13;q21)[1] / 46,XX,t(5;13)(q13;q21)[1] / 46,XX,t(5;9)(q22;q34)[1] / 46XX,t(1;15;13;13)(q32;q15;p12;q12),?t(4;11)(p16;q23)[1] / 46, XX[16] 4 20
2169 (71) 46,XX,t(3;3)(p25; q21)[1]/46,XX,t(7;11)(p13;q22)[1] / 46,XX,t(9;16)(q22;q24)[1] / 46,XX,t(16;21)(q12-13;q22)[1] / 46,XX[16] 4 20
2358 (77) 46,XX,t(4;5)(q35;q11.2)[2] / 46,XX,t(3;6)(q24;p25)[1] / 46,XX, add(10)(p13),−15,+mar[1] /46,XX[16] 4 20
2547 (83) 46,XX,t(2;16)(q13;q24)[1] / 46,XX, t(2;4)(q37;q31)[1] / 46,XX,add(1)(p13),?add(3)(p25),der(22)t(1;22)(p22;q11.2)[1] / 46,XX[17] 3 20
2792 (91) 46,XX,der(1)inv(1)(p13;q21)t(1;5)(p13;q11.2),der(5)t(1;5)(p13;q11.2)[1] / 46,XX[19] 3 20
3184 (104) 46,XX,−4,add(5)(p15),−10,der(11)(q23),−12,−13,+4mar[1] / 46,XX,t(16;22)(q24;q11.2)[1] /46,XX[18] 2 20
3821 (125) 45,XX,−2,t(3;9)(p25;q22)[1] / 46,XX,inv(11)(p15;q13)[1]/46, XX t(1;5)(p32;q13)[1] /46,XX,−4,−5,−8,−10,−22,+5mar[1] / 47,XX,+5[1] / 46,XX[15] 5 20
4211 (138) 44,XX,t(1;6)(q12;q21),−4,−13[1] / 46,XX,inv(10)(q11.2q24)[1] / 46,XX[18] 2 20
Total number of analyzed cells after the transplant 50 299∗Potential clone. .e results of chromosomal analysis of bone marrow cells at several time points after allo-HSCT are shown above.
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(17p), or patients who are refractory to repeated chemo-
immunotherapies [4]. Transformation into more aggressive
lymphoma, called as Richter syndrome, also could be
considered for the indication of allo-HSCT [8].
In the current case, non-myeloablative allo-HSCT was
performed after achieving ﬁrst hematological remission of
CLL based on the aggressive clinical presentation at di-
agnosis with the suspect of Richter syndrome and the
persistence of MRD. Later, Richter syndrome was thought to
be inaccurate because the frequencies of blastic lymphocytes
at the diagnosis did not fulﬁll the criteria, and thus, argu-
ments may remain regarding the clinical decision for allo-
HSCT. Such patient would be treated with the other
treatment options if current chemoimmunotherapies would
be applicable. Anyhow, autologous bone marrow recovery
resulted. No donor-type hematopoiesis was detectable at the
level with STR-PCR, and there was no apparent GVHD.
Autologous marrow recovery after allo-HSCT is sometimes
observed in patients with chronic myelogenous leukemia, in
themajority of those who eventually demonstrate the disease
relapse [9, 10]. However, the long-term consequence after
the post-allo-HSCT autologous marrow recovery in CLL is
unclear. Given that we were not able to ﬁnd any report
describing a long-term outcome after autologous marrow
recovery in CLL, the clinical course of the current case is
considered to be extremely rare. .ere is no good evidence-
based scenario that explains the mechanism how CLL cells
were eradicated and have been controlled for a long time.
One possibility may be that a very short-term allogeneic
immune reaction soon after the transplantation has helped
eradicate residual CLL cells. In any case, low tumor burden
and non-myeloablative regimen with very weak cytotoxicity
may have caused the recovery of patient’s own hemato-
poietic system and durable remission of disease.
We also showed the results of repeated cytogenetic
analyses, demonstrating RCA over 10 years after autologous
marrow recovery (Table 2). RCA represents nonclonal
chromosomal aberrations and are caused by external factors
such as radiation, chemical, or others [11, 12], among which
experiences of high-dose ionizing radiation are the most
abundant [13, 14]. In the literature regarding cord blood
transplant for a lethally irradiated nuclear accident victim
[15], clonal and nonclonal chromosomal aberrations within
100 days after the transplant were documented. Given the
fact that irradiation exposure is associated with an increased
risk for MDS development even 40–60 years after the ex-
posure [2], and careful follow-up is mandatory.
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